4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CStone Pharmaceuticals (2616) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 136 employees. Its market capitalization is roughly CNY 8 billion. In the fiscal year ended 2025-12-31, 2616 reported CNY 270M in revenue and (CNY 437M) in net income.
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 270M | CNY 407M | CNY 464M | CNY 481M | — |
| Gross Profit | CNY 51M | CNY 240M | CNY 304M | CNY 278M | — |
| Operating Income (EBIT) | (CNY 418M) | (CNY 92M) | (CNY 580M) | (CNY 903M) | — |
| Net Income | (CNY 437M) | (CNY 91M) | (CNY 367M) | (CNY 903M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 1.4B | CNY 1.4B | CNY 1.7B | CNY 1.6B | — |
| Total Liabilities | CNY 742M | CNY 1.0B | CNY 1.2B | CNY 1.2B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2616 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms